Treatment of demyelinating diseases
US12318380B2 · kind B2 · utility
0Cited by
24References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 30, 2022 |
| Grant date | Jun 3, 2025 |
| Priority date | — |
| Expiry date | Dec 6, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.